# UB Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ub-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.ubiqbiopharm.com
- Total disclosed funding: $0.8M
- Latest round: Seed (Jul 10, 2023)
- Investors on record: 2

## About

Based in Seoul, South Korea, founded in 2019, Grassmedi Co., Ltd. trading under the name UB Pharmaceutical, operates as a veterinary pharmaceutical company that specializes in developing healthcare products for pets, focusing on medicines and wellness solutions. In July 2023, UB Pharmaceutical raised KRW 1 billion in seed funding led by investor Atinum Ventures, with participation from another investor FuturePlay. The firm as of January 2025, is led by its CEO, Jinsik Choi, and President, Seo Young.

The company specializes in the development, production, and distribution of raw pharmaceutical products to advanced drug delivery technologies such as pet medicines and non-prescription products. Their diverse portfolio includes anti-inflammatory treatments, chronic pain medication, and advanced dermatological solutions, as well as innovative non-prescription items such as dental care products, skin soothing mists, and acne kits for pets. UB Pharmaceutical also operates a Contract Research Organization (CRO) division, providing preclinical and non-clinical services to assist in drug development and regulatory approval processes.

## Funding rounds

- Seed, Jul 10, 2023, $0.8M — FuturePlay, Atinum Ventures

## Investors

- FuturePlay (https://capitalatlas.ai/funds/futureplay) — Seed
- Atinum Ventures (https://capitalatlas.ai/funds/atinum-ventures) — Seed